FindTrial
Sign In

Effect of oral herbal oil supplement (Cannabis Sativa L, Oenothera Biennis L) and advising diet with Hot nature on multiple sclerosis patients

Effect of oral herbal oil supplement (Cannabis Sativa L, Oenothera Biennis L) and advising diet with Hot nature on clinical signs and symptoms and inflammatory factors in patients with multiple sclerosis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT138804252195N1
Enrollment
99
Registered
2010-12-04
Start date
2010-10-27
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Demyelinating diseases of the central nervous system

Interventions

Intervention 1: Receiving 18-21g of oral supplement oil, (Cannabis Sativa L,Oenothera Biennis L), daily and advising diet with hot nature for 180 days. Intervention 2: Receiving 18-21g of oral supple
Treatment - Drugs
Placebo
Receiving 18-21g of oral supplement oil, (Cannabis Sativa L,Oenothera Biennis L), daily and advising diet with hot nature for 180 days.
Receiving 18-21g of oral supplement oil (Cannabis Sativa L,Oenothera Biennis L), daily for 180 days.
Receiving daily 18-21g of "Olive Oil" as placebo for 180 days.

Sponsors

Neurosciences Research Center (NSRC)
Lead Sponsor
Soheila Rezapour-Firouzi
Collaborator

Eligibility

Sex/Gender
All
Age
14 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All MS patients with clinical form of relapsing-remitting type, EDSS =<6 Exclusion criteria: Secondary or primary progressive MS, patients suffering concomitantly from another chronic diseases such as active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus, other neurological, inflammatory, or autoimmune diseases, Pregnancy, Corticostoid use, Acute phase of MS relapse

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Serum IL-4 concentration. Timepoint: Before intervention -6 month after intervention. Method of measurement: ELISA test.;Serum IFN-Y concentration. Timepoint: Before intervention -6 month after intervention. Method of measurement: ELISA test.;EDSS (Extended disability status score ). Timepoint: Before intervention - 3month after intervention-6 month after intervention. Method of measurement: Clinical examination.;Urinary PLA2 concentration. Timepoint: Before intervention -6 month after intervention. Method of measurement: ELISA test.;Blood cells Polyunsaturated Fatty Acid. Timepoint: Before intervention - 6 month after intervention. Method of measurement: GC test.;Serum PLA2 concentration. Timepoint: before intervention -6month after intervention. Method of measurement: ELISA test.;Serum IL-17 concentration. Timepoint: Before intervention - 6 month after intervention. Method of measurement: ELISA test.;Blood cells delta-6-desaturase. Timepoint: Before intervention - 6 month after intervention. Method of measurement: ELISA test.—

Secondary

MeasureTime frame
Changes of MRI. Timepoint: before intervention - 6 month after intervention. Method of measurement: imaging.;Drug changes of symptomatic therapy. Timepoint: before intervention-3month after intervention-6 month after intervention. Method of measurement: Interview.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Seyed Rafi Aref Hosseini

Nutrition and Health Faculty

arefhosseinir@tbzmed.ac.ir, srarefhosseini@gmail.com00984113848757-00984113357580-3

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026